PFIZER REPORTS STRONG FIRST-QUARTER 2021 RESULTS
The Pharma Data
MAY 4, 2021
as well as growth from recent anti-infective product launches in international markets, partially offset by lower year-over-year volume for certain products globally due to a COVID-19-related surge in demand in the prior-year quarter, partially offset primarily by lower revenues for: Prevnar 13 in the U.S., Amy Rose 212.733.7410.
40 
Let's personalize your content